Both epilepsy and anti‐seizure medications affect bone metabolism in children with self‐limited epilepsy with centrotemporal spikes
Xiu‐Yu Shi,Jun Ju,Qian Lu,Lin‐Yan Hu,Ya‐Ping Tian,Guang‐Hong Guo,Zhi‐Sheng Liu,Ge‐Fei Wu,Hong‐Min Zhu,Yu‐Qin Zhang,Dong Li,Li Gao,Liu Yang,Chun‐Yu Wang,Jian‐Xiang Liao,Ji‐Wen Wang,Shui‐Zhen Zhou,Hua Wang,Xiao‐Jing Li,Jing‐Yun Gao,Li Zhang,Xiao‐Mei Shu,Dan Li,Yan Li,Chun‐Hong Chen,Xiu‐Ju Zhang,Jian‐Min Zhong,Qiong‐Xiang Zhai,Yan‐Hong Sun,Xue‐Feng Lin,Rong‐Na Ren,Fei Yin,Yan‐Hui Chen,Fei‐Yong Jia,Zhi‐Xian Yang,Ju‐Li Wang,Zhe‐Zhi Xia,Li‐Wen Wang,Rong Luo,Li‐Ping Zou
DOI: https://doi.org/10.1111/epi.17733
IF: 6.74
2023-08-02
Epilepsia
Abstract:Objective Bone metabolism can be influenced by a range of factors. We selected children with self‐limited epilepsy with centrotemporal spikes (SeLECTS) and lifestyles similar to those of healthy children to control for the confounding factors that may influence bone metabolism. We aimed to identify the specific effects of epilepsy and/or ASMs on bone metabolism. Methods Patients with SeLECTS were divided into untreated group and monotherapy group, and the third group was a healthy control group. We determined the levels of various biochemical markers of bone metabolism, including procollagen type I nitrogenous propeptide (PINP), alkaline phosphatase (ALP), osteocalcin (OC), collagen type I cross‐linked C‐telopeptide (CTX), calcium, magnesium, phosphorus, parathyroid hormone (PTH), vitamin D3 (VD3). Results 1487 (from 19 centers) were diagnosed with SeLECTS. 1032 subjects were analyzed, including 117 patients who did not receive any ASMs (untreated group), 643 patients who received only one ASM (monotherapy group), and 272 children in the healthy control group. Except for VD3, other bone metabolism of the three groups were not identical (p<0.001). Bone metabolism was significantly lower in untreated group than the healthy control (p<0.05). There were significant differences between monotherapy and healthy control group in the level of many markers. However, comparing the monotherapy and untreated groups, results were totally different; oxcarbazepine, levetiracetam, topiramate had no significant effect on bone metabolism. Phosphorus and magnesium were significantly lower in valproic acid group than the untreated group (adjusted p<0.05, Cliff's delta 0.282‐0.768). CTX was significantly higher in the lamotrigine group than in the untreated group (adjusted p=0.012, Cliff's delta=0.316). Significance Epilepsy can affect many aspects of bone metabolism. After controlling epilepsy and other confounders that affect bone metabolism, we found that the effects of ASMs on bone metabolism differed. Oxcarbazepine, levetiracetam, topiramate did not affect bone metabolism, and lamotrigine corrected some of the abnormal markers of bone metabolism in epileptic patients.
clinical neurology